{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:15:14Z","timestamp":1787030114510,"version":"build-2736575974"},"reference-count":86,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Monkeypox disease (MPX) is currently considered a global threat after COVID-19. European Medicines Agency (EMA) approved Tecovirimat in capsule dosage form (200 mg) as the first treatment for MPX in January 2022. This article highlights Tecovirimat\u2019s development and patent literature review and is believed to benefit the scientists working on developing MPX treatments. The literature for Tecovirimat was gathered from the website of SIGA Technologies (developer of Tecovirimat), regulatory agencies (EMA, United States Food and Drug Administration (USFDA), and Health Canada), PubMed, and freely accessible clinical\/patent databases. Tecovirimat was first recognized as an anti-orthopoxvirus molecule in 2002 and developed by SIGA Technologies. The USFDA and Health Canada have also recently approved Tecovirimat to treat smallpox in 2018 and 2021, respectively. The efficacy of Tecovirimat was verified in infected non-human primates (monkeys) and rabbits under the USFDA\u2019s Animal Rule. Most clinical studies have been done on Tecovirimat\u2019s safety and pharmacokinetic parameters. The patent literature has revealed inventions related to the capsule, injection, suspension, crystalline forms, amorphous form, and drug combinations (Tecovirimat + cidofovir) and process for preparing Tecovirimat. The authors foresee the off-label use of Tecovirimat in the USA and Canada for MPX and other orthopoxvirus infections. The authors also trust that there is immense scope for developing new Tecovirimat-based treatments (new drug combinations with other antivirals) for orthopoxvirus and other viral diseases. Drug interaction studies and drug resistance studies on Tecovirimat are also recommended. Tecovirimat is believed to handle the current MPX outbreak and is a new hope of biosecurity against smallpox or orthopoxvirus-related bioterrorism attack.<\/jats:p>","DOI":"10.3390\/v14091870","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T02:09:36Z","timestamp":1661911776000},"page":"1870","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-8667","authenticated-orcid":false,"given":"Mazen","family":"Almehmadi","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-7748","authenticated-orcid":false,"given":"Mamdouh","family":"Allahyani","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahad Amer","family":"Alsaiari","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-0461","authenticated-orcid":false,"given":"Mohammed Kanan","family":"Alshammari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, Rafha Central Hospital, North Zone, Rafha 76312, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrar Saleh","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Primary Healthcare Center, Mecca 24341, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-5504","authenticated-orcid":false,"given":"Khansa Hamza","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Cardiac Sciences, College of Medicine, King Saud University, Riyadh 11472, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0500-4601","authenticated-orcid":false,"given":"Lojain Ibrahim","family":"Alsubaihi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, Prince Sultan Armed Forces Hospital, Medina 42313, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-0828","authenticated-orcid":false,"given":"Mehnaz","family":"Kamal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad Saleh","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Shaqra University, Dawadmi, Riyadh 17649, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atheer Nasser","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afeefah Awaid","family":"Aldhafeeri","sequence":"additional","affiliation":[{"name":"Department of Nursing, North Area Armed Forced Hospital, King Khalid Military City, Hafr Al-Batin 31991, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-1040","authenticated-orcid":false,"given":"Mohd","family":"Imran","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Multinational monkeypox outbreak: What do we know and what should we do?","volume":"1971","author":"Memariani","year":"2022","journal-title":"Ir. J. Med. Sci."},{"key":"ref_2","first-page":"29","article-title":"Monkeypox outbreak: A novel threat after COVID-19?","volume":"9","author":"Zhang","year":"2022","journal-title":"Mil. Med. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.3346\/jkms.2022.37.e188","article-title":"Once bitten, twice shy: Our attitude towards monkeypox","volume":"37","author":"Yoo","year":"2022","journal-title":"J. Korean Med. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2666-5247(22)00153-7","article-title":"Global human monkeypox outbreak: Atypical presentation demanding urgent public health action","volume":"3","author":"Out","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fpubh.2018.00241","article-title":"Emergence of monkeypox as the most important orthopoxvirus infection in humans","volume":"6","author":"Van","year":"2018","journal-title":"Front. Public Health"},{"key":"ref_6","unstructured":"Moore, M., and Zahra, F. (2022). Monkeypox. StatPearls [Internet]. Treasure Island (FL), StatPearls Publishing."},{"key":"ref_7","unstructured":"World Health Organization (2022, July 11). Monkeypox. Available online: https:\/\/www.who.int\/emergencies\/emergency-events\/item\/monkeypox."},{"key":"ref_8","unstructured":"World Health Organization (2022, July 11). Multi-Country Monkeypox Outbreak: Situation Update. Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON392."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1473-3099(22)00228-6","article-title":"NHS England High Consequence Infectious Diseases (Airborne) Network. Clinical features and management of human monkeypox: A retrospective observational study in the UK","volume":"22","author":"Adler","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jmv.25348","article-title":"A review of the monkeypox virus and a recent outbreak of skin rash disease in Nigeria","volume":"91","author":"Kabuga","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_11","unstructured":"Centers for Disease Control and Prevention (2022, July 11). Monkeypox Symptoms, Available online: https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/symptoms.html."},{"key":"ref_12","unstructured":"World Health Organization (2022, July 11). Monkeypox. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/monkeypox."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Brown, K., and Leggat, P.A. (2016). Human monkeypox: Current state of knowledge and implications for the Future. Trop. Med. Infect. Dis., 1.","DOI":"10.3390\/tropicalmed1010008"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100989","DOI":"10.1016\/j.nmni.2022.100989","article-title":"The new face of monkeypox virus: An emerging global emergency","volume":"47","author":"Jain","year":"2022","journal-title":"New Microbes New Infect."},{"key":"ref_15","unstructured":"(2022, July 11). TPOXX. Available online: https:\/\/www.rxlist.com\/tpoxx-drug.htm#clinpharm."},{"key":"ref_16","unstructured":"European Medicines Agency (2022, July 11). Tecovirimat SIGA. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecovirimat-siga."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s40265-018-0967-6","article-title":"Tecovirimat: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_18","unstructured":"European Medicines Agency (2022, July 11). Assessment Report: Tecovirimat SIGA, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/tecovirimat-siga-epar-public-assessment-report_en.pdf."},{"key":"ref_19","unstructured":"Center for Drug Evaluation and Research (2022, July 11). Product Quality Review, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208627Orig1s000ChemR.pdf."},{"key":"ref_20","unstructured":"SIGA Human BioArmor (2022, July 11). TPOXX (Tecovirimat) Fact Sheet. Available online: https:\/\/www.siga.com\/wp-content\/uploads\/2022\/06\/TPOXXFactSheet_2022.pdf."},{"key":"ref_21","unstructured":"SIGA Human BioArmor (2022, July 11). Smallpox. Available online: https:\/\/www.siga.com\/wp-content\/uploads\/2022\/06\/CorporateBrochure_2022.pdf."},{"key":"ref_22","unstructured":"(2022, July 11). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Tecovirimat, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm."},{"key":"ref_23","unstructured":"(2022, July 11). Product Monograph. TPOXX. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00063782.PDF."},{"key":"ref_24","unstructured":"Government of Canada (2022, July 11). Register of Innovative Drugs. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/register-innovative-drugs.html."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fvl.11.27","article-title":"Development of the small-molecule antiviral ST-246 as a smallpox therapeutic","volume":"6","author":"Grosenbach","year":"2011","journal-title":"Future Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3390\/v2112409","article-title":"Development of ST-246 for treatment of poxvirus infections","volume":"2","author":"Jordan","year":"2010","journal-title":"Viruses"},{"key":"ref_27","unstructured":"Jordan, R., Bailey, T.R., and Rippin, S.R. (2004). Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases. (WO2,004,112,718A2), PCT Patent."},{"key":"ref_28","unstructured":"Tyavanagimatt, S.R., Stone, M.A.C.L., Weimers, W.C., Nelson, D., Bolken, T.C., Hruby, D.E., O\u2019neill, M.H., Sweetapple, G., and Mccloughan, K.A. (2016). Polymorphic Forms of ST-246 and Methods of Preparation. (9,339,466B2), U.S. Patent."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/AAC.01596-08","article-title":"ST-246 antiviral efficacy in a non-human primate monkeypox model: Determination of the minimal effective dose and human dose justification","volume":"53","author":"Jordan","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","unstructured":"(2022, July 11). Highlights of Prescribing Information. TPOXX, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208627s000lbl.pdf."},{"key":"ref_31","unstructured":"(2022, July 11). Summary of Product Characteristics. Tecovirimat SIGA. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecovirimat-siga-epar-product-information_en.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral tecovirimat for the treatment of smallpox","volume":"379","author":"Grosenbach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J. Virol."},{"key":"ref_34","unstructured":"(2022, July 11). Highlights of Prescribing Information. TPOXX, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214518s000lbl.pdf."},{"key":"ref_35","unstructured":"SIGA Technologies (2022, July 11). FDA Advisory Committee Briefing Document: Tecovirimat for the Treatment of Smallpox Disease, Available online: https:\/\/www.fda.gov\/media\/112808\/download."},{"key":"ref_36","unstructured":"U.S. National Library of Medicines (2022, July 11). ClinicalTrials Database, Available online: https:\/\/www.clinicaltrials.gov\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1128\/AAC.00904-12","article-title":"Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers","volume":"56","author":"Chinsangaram","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1128\/AAC.06090-11","article-title":"Pharmacokinetic comparison of a single oral dose of polymorph form I versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers","volume":"56","author":"Chinsangaram","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1128\/AAC.01689-09","article-title":"Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects","volume":"54","author":"Jordan","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.01303-07","article-title":"Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor","volume":"52","author":"Jordan","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.00959-12","article-title":"Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans","volume":"57","author":"Leeds","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","unstructured":"Espacenet (2022, July 11). Patent Search. Available online: https:\/\/worldwide.espacenet.com\/patent\/search."},{"key":"ref_43","unstructured":"WIPO IP Portal (2022, July 11). Patentscope. Available online: https:\/\/patentscope.wipo.int\/search\/en\/structuredSearch.jsf."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/13543776.2021.1939308","article-title":"Mucormycosis medications: A patent review","volume":"31","author":"Imran","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/13543776.2021.1902990","article-title":"Synthetic molecules as DprE1 inhibitors: A patent review","volume":"31","author":"Imran","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/13543776.2022.2045948","article-title":"Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: A patent review from 1998 to 2021","volume":"32","author":"Imran","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Imran, M., Asdaq, S.M.B., Khan, S.A., Unnikrishnan, M.D., Alamri, A.S., Alsanie, W.F., Alhomrani, M., Mohzari, Y., Alrashed, A., and AlMotairi, M. (2021). Innovations and patent trends in the development of USFDA approved protein kinase inhibitors in the last two decades. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080710"},{"key":"ref_48","unstructured":"Ordan, R., Bailey, T.R., and Rippin, S.R. (2012). Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases. (8,124,643B2), U.S. Patent."},{"key":"ref_49","unstructured":"Jordan, R., Bailey, T.R., and Rippin, S.R. (2010). Compounds, Compositions, and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases. (7,737,168B2), U.S. Patent."},{"key":"ref_50","unstructured":"Jordan, R.F., Bailey, T.R., Rippin, S.R., and Dai, D. (2014). Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases. (8,802,714B2), U.S. Patent."},{"key":"ref_51","unstructured":"Jordan, R., Bailey, T.R., Rippin, S.R., and Dai, D. (2013). Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases. (8,530,509B2), U.S. Patent."},{"key":"ref_52","unstructured":"Tyavanagimatt, S.R., Anderson, M.A.C.L.S., Weimers, W., Kasi, G.K., Samuel, N.K.P., Bolken, T.C., and Hruby, D.E. (2020). ST-246 Liquid Formulations and Methods. (10,576,165B2), U.S. Patent."},{"key":"ref_53","unstructured":"Tyavanagimatt, S.R., Stone, M.A.C.L., Weimers, W.C., Kasi, G.K., Samuel, P.N.K., Bolken, T., and Hruby, D.E. (2016). ST-246 Liquid Formulations. (9,233,097B2), U.S. Patent."},{"key":"ref_54","unstructured":"Tyavanagimatt, S.R., Anderson, M.A.C.L.S., Weimers, W., Kasi, G.K., Samuel, N.K.P., Bolken, T.C., and Hruby, D.E. (2018). ST-246 Liquid Formulations and Methods. (9,907,859B2), U.S. Patent."},{"key":"ref_55","unstructured":"Jordan, R.F., Bailey, T.R., Rippin, S.R., and Dai, D. (2011). Chemicals, Compositions, and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases. (8,039,504B2), U.S. Patent."},{"key":"ref_56","unstructured":"Jordan, R., Bailey, T.R., and Rippin, S.R. (2011). Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases. (7,956,197B2), U.S. Patent."},{"key":"ref_57","unstructured":"Tyavanagimatt, S.R., Anderson, M.A.C.L.S., Weimers, W.C., Nelson, D., Bolken, T.C., Hruby, D.E., O\u2019Neill, M.H., Sweetapple, G., and McCloughan, K.A. (2017). Polymorphic Forms of ST-246 and Methods of Preparation. (9,744,154B2), U.S. Patent."},{"key":"ref_58","unstructured":"Tyavanagimatt, S.R., Anderson, M.A.C.L.S., Weimers, W.C., Nelson, D., Bolken, T.C., Hruby, D.E., O\u2019Neill, M.H., Sweetapple, G., and McCloughan, K.A. (2018). Polymorphic Forms of ST-246 and Methods of Preparation. (10,045,964B2), U.S. Patent."},{"key":"ref_59","unstructured":"Tyavanagimatt, S.R., Anderson, M.A.C.L.S., Weimers, W.C., Nelson, D., Bolken, T.C., Hruby, D.E., O\u2019Neill, M.H., Sweetapple, G., and McCloughan, K.A. (2019). Polymorphic Forms of ST-246 and Methods of Preparation. (10,406,137B2), U.S. Patent."},{"key":"ref_60","unstructured":"Tyavanagimatt, S.R., Anderson, M.A.C.L.S., Weimers, W.C., Nelson, D., Bolken, T.C., Hruby, D.E., O\u2019Neill, M.H., Sweetapple, G., and McCloughan, K.A. (2021). Polymorphic Forms of ST-246 and Methods of Preparation. (10,933,050B2), U.S. Patent."},{"key":"ref_61","unstructured":"Jordan, R., Bailey, T.R., Rippin, S.R., and Dai, D. (2015). Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases. (9,045,418B2), U.S. Patent."},{"key":"ref_62","unstructured":"Tyavanagimatt, S.R., Anderson, M.A.C.L.S., Weimers, W., Kasi, G.K., Samuel, N.K.P., Bolken, T.C., and Hruby, D.E. (2018). ST-246 Liquid Formulations and Methods. (10,124,071B2), U.S. Patent."},{"key":"ref_63","unstructured":"Tyavanagimatt, S.R., Anderson, M.A.C.L.S., Weimers, W., Kasi, G.K., Samuel, N.K.P., Bolken, T.C., and Hruby, D.E. (2020). ST-246 Liquid Formulations and Methods. (10,864,282B2), U.S. Patent."},{"key":"ref_64","unstructured":"Tyavanagimatt, S.R., Reeves, M., Samuel, N.K.P., Priebe, S., Tan, Y., and Hruby, D.E. (2020). Rehydration of Micronized Tecovirimat Monohydrate. (10,716,759B2), U.S. Patent."},{"key":"ref_65","unstructured":"Tyavanagimatt, S.R., Reeves, M., Samuel, N.K.P., Priebe, S., Tan, Y., and Hruby, D.E. (2019). Rehydration of Micronized Tecovirimat monohydrate. (10,406,103B2), U.S. Patent."},{"key":"ref_66","unstructured":"Tyavanagimatt, S.R., Samuel, N.K.P., Paz, J., Tan, Y., and Hruby, D.E. (2017). Amorphous Tecovirimat Preparation. (9,670,158B2), U.S. Patent."},{"key":"ref_67","unstructured":"Tyavanagimatt, S.R., Samuel, N.K.P., Paz, J., Tan, Y., and Hruby, D.E. (2018). Amorphous Tecovirimat Preparation. (9,889,119B2), U.S. Patent."},{"key":"ref_68","unstructured":"Dai, D. (2018). Methods of Preparing Tecovirimat. (10,155,723B2), U.S. Patent."},{"key":"ref_69","unstructured":"Dai, D. (2020). Methods of Preparing Tecovirimat. (10,662,155B2), U.S. Patent."},{"key":"ref_70","unstructured":"Dai, D. (2017). Methods of Preparing Tecovirimat. (9,546,137B2), U.S. Patent."},{"key":"ref_71","unstructured":"Dai, D. (2018). Methods of Preparing Tecovirimat. (9,862,683B2), U.S. Patent."},{"key":"ref_72","unstructured":"Jordan, R.F., Bailey, T.R., Rippin, S.R., and Dai, D. (2010). Chemicals, Compositions, and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases. (7,687,641B2), U.S. Patent."},{"key":"ref_73","unstructured":"Dai, D., Bailey, T.R., Rippin, S.R., and Jordan, R. (2016). Chemicals, Compositions, and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases. (2,012,268,859B2), Australian Patent."},{"key":"ref_74","unstructured":"Tyavanagimatt, S.R., Holt, K., Tan, Y., Anderson, M.A.C.L.S., and Hruby, D.E. (2021). ST-246 (Tecovirimat Monohydrate) Suspension Formulations. (2,021,212,987A1), U.S. Patent."},{"key":"ref_75","unstructured":"Zhong, W., Yang, M., Gong, W., Wang, Y., Gao, C., Zhou, X., and Li, S. (2022). Injectable Pharmaceutical Composition of Tecovirimat and Preparation Method Thereof. (11,369,587B2), U.S. Patent."},{"key":"ref_76","unstructured":"Zhong, W., Yang, M., Gong, W., Wang, Y., Gao, C., Zhou, X., and Li, S. (2022). Oral Pharmaceutical Composition of Tecovirimat and Preparation Method Thereof. (11,318,115B2), U.S. Patent."},{"key":"ref_77","unstructured":"Dai, Q., Dong, M., Yu, S., Peng, B., Wang, Y., and Zhu, M. (2013). Tecovirimat Dry Suspension and Preparation Method Thereof. (102,406,617B), Chinese Patent."},{"key":"ref_78","unstructured":"Almond, M.R., and Painter, G.R. (2014). Compounds, Compositions and Methods for the Treatment of Poxvirus Infections. (8,642,577B2), U.S. Patent."},{"key":"ref_79","unstructured":"Szalay, A.A., Chen, N., and Yu, Y.A. (2014). Use of a Chemotherapeutic Agent in the Preparation of a Medicament for Treating or Ameliorating an Adverse Side Effect Associated with Oncolytic Viral Therapy. (2,202,297B1), European Patent."},{"key":"ref_80","unstructured":"Dai, Q., Dong, M., and Hu, J. (2011). Compound ST-246 Containing a Crystal Water, crystal Thereof and Preparation Method Thereof. (101,445,478B), Chinese Patent."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14787210.2020.1819791","article-title":"An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications","volume":"19","author":"Russo","year":"2021","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/cpt.1427","article-title":"Translation of drug interaction knowledge to actionable labeling","volume":"105","author":"Tran","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_83","unstructured":"SIGA Human BioArmor (2022, July 11). Press Releases. Available online: https:\/\/investor.siga.com\/press-releases."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Imran, M., Fatima, W., Alzahrani, A.K., Suhail, N., Alshammari, M.K., Alghitran, A.A., Alshammari, F.N., Ghoneim, M.M., Alshehri, S., and Shakeel, F. (2022). Development of therapeutic and prophylactic zinc compositions for use against COVID-19: A glimpse of the trends, inventions, and patents. Nutrients, 14.","DOI":"10.3390\/nu14061227"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Imran, M., Thabet, H.K., Alaqel, S.I., Alzahrani, A.R., Alshammari, M.K., Kamal, M., Diwan, A., Asdaq, S.M.B., and Alshehri, S. (2022). The therapeutic and prophylactic potential of quercetin against COVID-19: An outlook on the clinical studies, inventive compositions, and patent literature. Antioxidants, 11.","DOI":"10.3390\/antiox11050876"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.3390\/molecules27092750","article-title":"Nigella sativa L. and COVID-19: A glance at the anti-COVID-19 chemical constituents, clinical trials, inventions, and patent literature","volume":"27","author":"Imran","year":"2022","journal-title":"Molecules"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/9\/1870\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:15:01Z","timestamp":1760141701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/9\/1870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":86,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["v14091870"],"URL":"https:\/\/doi.org\/10.3390\/v14091870","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}